Progress towards a Leishmania vaccine

Saudi Medical Journal

Volumn 27, Issue 7, 2006, Pages 942-950

  Tabbara, Khaled S ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CD4 ANTIGEN; DNA; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEISHMANIA ACTIVATED C KINASE; LEISHMANIA AMAZONENSIS EXTRACT; LEISHMANIA BRAZILIENSIS EXTRACT; LEISHMANIA GUYANENSIS EXTRACT; LEISHMANIA INITIATION FACTOR; LEISHMANIA LIPOPHOSPHOGLYCAN; LEISHMANIA MAJOR EXTRACT; LEISHMANIA VACCINE; LIVE VACCINE; MEGLUMINE; NAKED DNA; NATURAL PRODUCT; PHOSPHORYL LIPID A; PLACEBO; RIBOSOME PROTEIN; SUBUNIT VACCINE; SURFACE ANTIGEN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CD4+ CD25+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNITY; INCIDENCE; INFECTION; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LEISHMANIASIS; LIFESPAN; MIDDLE EAST; NONHUMAN; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANIMALS; CLINICAL TRIALS; HUMANS; LEISHMANIA; LEISHMANIASIS; MIDDLE EAST; PROTOZOAN VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 33750306182     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Arita I. Standardization of smallpox vaccines and the eradication program - a WHO perspective. Dev Biol Stand 1999; 100: 31-37.
2. Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol 2004; 2: 473-482.
3. Price VL, Kieny MP. Vaccines for parasitic diseases. Curr Drug Targets Infect Disord 2001; 1: 315-324.
4. Ryan ET. Malaria: epidemiology, pathogenesis, diagnosis, prevention, and treatment - an update. Curr Clin Top Infect Dis 2001; 21: 83-113.
5. Berman J. Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment. Curr Infect Dis Rep 2005; 7: 33-38.
6. Ruppel A, Kennedy MW, Kusel JR. Schistosomiasis immunology, epidemiology and diagnosis. Trends Parasitol 2002; 18: 50-52.
7. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-318.
8. Feliciangeli MD. Vectors of leishmaniases in Venezuela. Parassitologia 1991; 33 Suppl: 229-236.
9. Killick-Kendrick, R. The life-cycle of Leishmania in the sandfly with special reference to the form infective to the vertebrate host. Ann Parasitol Hum Comp 1990; 65 Suppl 1: 37-42.
10. Bretscher PA, Menon JN, Ogunremi O. Towards a strategy of universally efficacious vaccination against pathogens uniquely susceptible to cell-mediated attack. J Biotechnol 1996; 44: 1-4.
11. Al-Hilli F. Leishmaniasis in Bahrain. Bahrain Medical Bulletin 1982; 4: 88-91.
12. Al-Zahrani MA, Peters W, Evans DA, Smith V, Ching Chin I. Leishmania infecting man and wild animals in Saudi Arabia. 6. Cutaneous leishmaniasis of man in the southwest. Trans R Soc Trop Med Hyg 1989; 83: 621-628.
13. Al-Zahrani MA, Peters W, Evans DA, Smith V, Ching CI. Leishmania infecting man and wild animals in Saudi Arabia. 5. Diversity of parasites causing visceral leishmaniasis in man and dogs in the south-west. Trans R Soc Trop Med Hyg 1989: 83:503-509.
14. Elbihari S, Kawasmeh ZA, Al-Naiem A, Al-Atiya S. Leishmania infecting man and wild animals in Saudi Arabia. 3. Leishmaniasis in Psammomys obesus Cretzschmar in Al-Ahsa oasis. Trop Med Parasitol 1987; 38: 89-92.
15. Aljeboori, TI, Evans DA. Leishmania spp. in Iraq. Electrophoretic isoenzyme patterns. II. Cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1980; 74: 178-184.
16. Aljeboori TI, Evans DA. Leishmania spp. in Iraq. Electrophoreticisoenzymepatterns. I. Visceralleishmaniasis. Trans R Soc Trop Med Hyg 1980; 74: 169-177.
17. Ardehali S, Moattari A, Hatam GR, Hosseini SM, Sharifi I. Characterization of Leishmania isolated in Iran: 1. Serotyping with species specific monoclonal antibodies. Acta Trop 2000; 75: 301-307.
18. Dereure J, Rageh HA, Daoud W, Rioux JA. [Ecoepidemiology of visceral and cutaneous leishmaniasis in the Arab Republic of Yemen. II. A survey using intradermal reaction to leishmanin in a zone of mixed infestation with Leishmania tropica, L. donovani and L. infantum]. Bull Soc Pathol Exot Filiales 1989; 82: 665-668.
19. Haidar NA, Diab AB, El-Sheik AM. Visceral Leishmaniasis in children in the Yemen. Saudi Med J 2001; 22: 516-519.
20. Scrimgeour EM, Windsor JJ, Shetty MK, Banodkar DD, Lambson B, Barker DC, et al. Leishmania tropica is a probable cause of cutaneous leishmaniasis in the Sultanate of Oman: case report in a Pakistani resident. Trans R Soc Trop Med Hyg 1999; 93: 233-234.
21. Scrimgeour EM, Mehta FR, Suleiman AJ. Infectious and tropical diseases in Oman: a review. Am J Trop Med Hyg 1999: 61: 920-925.
22. El-Saaran AM, Harries JR. Visceral leishmaniasis in Dubai. Trans R Soc Trop Med Hyg 1979; 73: 475.
23. Ashford RW, Rioux JA, Jalouk L, Khiami A, Dye C. Evidence for a long-term increase in the incidence of Leishmania tropica in Aleppo, Syria. Trans R Soc Trop Med Hyg 1993; 87: 247-249.
24. Dereure J, Rioux JA, Khiami A, Pratlong F, Perieres J, Martini A. [Ecoepidemiology of leishmaniases in Syria. 2 - Presence, in dogs, of Leishmania infantum Nicolle and Leishmania tropica (Wright) (Kinetoplastida-Trypanonomatidae)]. Ann Parasitol Hum Comp 1991; 66: 252-255.
25. Kamhawi S, Abdel-Hafez SK, Arbagi A. A new focus of cutaneous leishmaniasis caused by Leishmania tropica in northern Jordan. Trans R Soc Trop Med Hyg 1995; 89: 255-257.
26. Knio, KN, Baydoun E, Tawk R, Nuwayri-Salti N. Isoenzyme characterization of Leishmania isolates from Lebanon and Syria. Am J Trop Med Hyg 2000; 63: 43-47.
27. Nimri L, Soubani R, Gramiccia M. Leishmania species and zymodemes isolated from endemic areas of cutaneous leishmaniasis in Jordan. Kinetoplastid Biol Dis 2002; 1: 7.
28. Jumaian N, Kamhawi SA, Halalsheh M, Abdel-Hafez SK. Short report: outbreak of cutaneous leishmaniasis in a nonimmune population of soldiers in Wadi Araba, Jordan. Am J Trop Med Hyg 1998; 58: 160-162.
29. Saliba EK, Pratlong F, Dedet ZP, Saleh N, Khoury SA, Oumeish Oy, et al. Identification of Leishmania strains from Jordan. Ann Trop Med Parasitol 2004; 98: 677-683.
30. Saliba EK, Saleh N, Oumeish OY, Khoury S, Bisharat Z, Al-Ouran R. The endemicity of Leishmania tropica (zymodeme MON-137) in the Eira-Yarqa area of Salt District, Jordan. Ann Trop Med Parasitol 1997; 91: 453-459.
31. Rioux JA, Ashford RW, Khiami A. Eco-epidemiology of leishmaniases in Syria. 3. Leishmania major infection in Psammomys obesus provides clues to life history of the rodent and possible control measures. Ann Parasitol Hum Comp 1992; 67: 163-165.
32. Saliba EK, Disi AM, Ayed RE, Saleh N, Al-Younes H, Oumeish O, et al. Rodents as reservoir hosts of cutaneous leishmaniasis in Jordan. Ann Trop Med Parasitol 1994; 88: 617-622.
33. Nuwayri-Salti N, Nasr R, Haddad K, Chamat S, Usta J. Canine leishmaniasis in northern Lebanon. Ann Trop Med Parasitol 1997; 91: 221-222.
34. Center for Disease Control (CDC). Viscerotropic leishmaniasis in persons returning from Operation Desert Storm - 1990-1991. MMWR 1992; 41: 131-134.
35. Magill AJ, Grogl M, Gasser RA, Sun W Jr, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328: 1383-1387.
36. Magill AJ, Grogl M, Johnson SC, Gasser RA, Jr. Visceral infection due to Leishmania tropica in a veteran of Operation Desert Storm who presented 2 years after leaving Saudi Arabia. Clin Infect Dis 1994; 19: 805-806.
37. Nicolle C. Isolement et culture des corps de Leishman. Arch Inst Pasteur Tunis 1908; 2: 55-56.
38. Nicolle CH. Cultures de corps de Leishman isolet de la rate dans trois cas d'anemic sptenique infantile. Bull Soc Pathol Exot 1908; 1: 121.
39. Nicolle CM. Recherches sur le bouton d orient: cultures, reproduction experimental, immunization. Annales De I'Institut Pasteur 1910.
40. Row R. Curative value of Leishmania culture vaccine in oriental sore. British Medical Journal 1912.
41. Gupta BM. The experimental transmission of Oriental sore (causing generalized infection) in laboratory animals. Far East Assoc Trop Med Trans, 7th Cong Brit India 1928; 3: 34-35.
42. Berberian D. Vaccination and immunity against oriental sore. Trans R Soc Trop Med Hyg 1939.
43. Sokolova AN. Preventive vaccination with the living parasites of cutaneous leishmaniasis. Trans Turkmen Cutan-Venereol Inst Ashkhabad 1940; 11: 44.
44. Senekji HA, Beattie CP. Artificial infection and immunization of man with cultures of Leishmania tropica. Trans R Soc Trop Med Hyg 1941; 34: 415.
45. Berberian DA. Cutaneous leishmaniasis (oriental sore). IV. Vaccination against oriental sore with suspensions of Leishmania tropica. Arch Derm Syphilol 1944; 50: 234.
46. Katzenellenbogen I. Vaccination against oriental sore: report of results of five hundred and fifty-five inoculations. Arch Derma Syphilol 1944; 50: 239.
47. Kellina OI. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the USSR. Bull Soc Pathol Exot Filiales 1981; 74: 306-318.
48. Greenblatt CL. The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res 1980; 47: 259-285.
49. Serebriakov VA, Karakhodzhaeva S, Dzhumaev MD. [Effect of leishmanial vaccinations on the dynamics of immunity to diphtheria in conditions of secondary revaccination with adsorbed pertussis-diphtheria-tetanus vaccine]. Med Parazitol (Mosk) 1972; 41: 303-307.
50. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995; 89 Suppl 1: 83-88.
51. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001; 14: 229-243.
52. Alexander J. A radio-attenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana. Trans R Soc Trop Med Hyg 1982; 76: 646-649.
53. Howard JG, Nicklin S, Hale C, Liew FY. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol 1982; 129: 2206-2212.
54. Howard JG, Liew FY, Hale C, Nicklin S. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J Immunol 1984; 132: 450-455.
55. Sharifi I, Fekri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351: 1540-1543.
56. Castes M, Blackwell J, Trujillo D, Formica S, Cabrera M, Zorrilla G, et al. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferongamma production. Vaccine 1994; 12: 1041-1051.
57. Cabrera M, Blackwell JM, Castes M, Trujillo D, Convit J, Shaw MA. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 2000; 22: 73-79.
58. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, et al. A randomized, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17:466-472.
59. Fahey JR, Herman R. Relationship between delayed hypersensitivity response and acquired cell-mediated immunity in C57BL/6J mice infected with Leishmania donovani. Infect Immun 1985; 49: 447-451.
60. Swain SL, McKenzie DT, Weinberg AD, Hancock W. Characterization of T helper 1 and 2 cell subsets in normal mice. Helper T cells responsible for IL-4 and IL-5 production are present as precursors that require priming before they develop into lymphokine-secreting cells. J Immunol 1988; 141: 3445-3455.
61. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13: 151-177.
62. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
63. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990; 144: 4794-4797.
64. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet 2000;. 356: 1565-1569.
65. Satti IN, Osman HY, Daifalla NS, Younis SA, Khalil EA, Zijlstra EE, et al. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001; 19: 2100-2106.
66. Khalil EA, Elhassan AM, Zijlstra EE, Osman OF, Eljack IA, Ibrahim ME, et al. Safety and immunogenicity of an autoclaved Leishmania major vaccine. East Afr Med J 2000; 77: 468-470.
67. Kamil AA, Khalil EA, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003; 97: 365-368.
68. Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, Emamjomeh M, et al. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol 2003; 134: 303-308.
69. Alimohammadian MH, Khamesipour A, Darabi H, Firooz A, Malekzadeh S, Bahonar A, et al. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 2002; 21: 174-180.
70. Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, inummogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 1998; 177: 1352-1357.
71. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004; 22: 1320-1326.
72. Convit J, Ulrich M, Polegre MA, Avila A, Rodriguez N, Mazzedo Mi, et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 2004; 99: 57-62.
73. Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber F, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 2002; 41: 73-78.
74. Velez ID, del Pilar Agudelo S, Arbelaez MP, Gilchrist K, Robledo SM, Puerta JA, et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000; 94:698-703.
75. Velez ID, Gilchrist K, Arbelaez MP, Rojas CA, Puerta JA, Antunes CM, et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 2005; 99: 593-598.
76. Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, et al. LeIF: a recombinant Leishmania protein that induces an IL- 12-mediated Th1 cytokine profile. J Immunol 1998; 161: 6171-6179.
77. Olobo, JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, et al. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania "major surface glycoprotein" (gp63). Vet Parasitol 1995; 60: 199-212.
78. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD, et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002; 70: 4215-4225.
79. Kubar J, Fragaki K. Recombinant DNA-derived Leishmania proteins: from the laboratory to the field. Lancet Infect Dis 2005; 5: 107-114.
80. Alarcon JB, Waine GW, McManus DP. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv Parasitol 1999; 42: 343-410.
81. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-648.
82. Hasan UA, Abai AM, Harper DR, Wren BW, Morrow WJ. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 1999; 229: 1-22.
83. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186: 1137-1147.
84. Walker PS, Scharton KT, Rowton ED, Hengge U, Bouloc A, Udey MC, et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis [see comments]. Hum Gene Ther 1998; 9: 1899-1907.
85. Sjolander A, Baldwin TM, Curtis JM, Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 1998; 160: 3949-3957.
86. Titus RG, Ribeiro JM. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988; 239: 1306-1308.
87. Kamhawi S, Belkaid Y, Modi G, Rowton E, Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000; 290: 1351-1354.
88. Valenzuela JG, Belkaid Y, Garfield MK, Mendez S, Kamhawi S, Rowton ED, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001; 194: 331-342.
89. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000; 12: 456-463.
90. Azazy AA, Nasher ST, Ishaq A, Bin-Muhanna M, Chance ML. Detection of antileishmanial IgG antibodies and Leishmania-specific antigens in sera from Yemeni patients with visceral leishmaniasis. Ann Trop Med Parasitol 2003; 97: 689-695.
91. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin- 12 in a vaccine against Leishmania major. Science 1994; 263: 235-237.
92. Kong D, Belosevic M, Kunimoto DY. Immunization of BALB/c mice with mIFN-gamma-secreting Mycobacterium bovis BCG provides early protection against Leishmania major infection. Int J Parasitol 1997; 27: 349-353.
93. Xu D, McSorley SJ, Tedey L, Chatfield S, Dougan G, Chan WL, et al. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium. J Immunol 1998; 160: 1285-1289.
94. Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun 2003; 71: 5121-5129.
95. Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003; 2: 305-315.
96. Bradford WL, Day E, Martin F. Humoral antibody formation in infants aged 1 to 3 months injected with a triple (diphtheria-tetanus-pertussis) alum-precipitated antigen. Pediatrics 1949; 4: 711-718.
97. Reed SG, Campos-Neto A. Vaccines for parasitic and bacterial diseases. Curr Opin Immunol 2003; 15: 456-460.
98. Taha SM, Tabbara KS. Modulation of the immune response of Balb/c mice against Leishmania major by Imuvert. Int J Immunopharmacol 1997; 19: 443-449.
99. Tabbara KS, Al-Salem JA. The immunopotentiating effect of Listeriolysin O in the response against Leishmania major in BALB/c mice. Cent Europ J Immunology 2003; 28: 119-125.
100. Tabbara KS, Al-Azmi AS, Al-Salem JA. Coinfection with Listeria monocytogenes potentiates the response of BALB/c mice against Leishmania major. J Egypt Soc Parasitol 2004; 34: 349-366.
101. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194: 1497-1506.
102. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420: 502-507.
103. Brodskyn C, Beverley SM, Titus RG. Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro. Clin Exp Immunol 2000; 119: 299-304.
104. Spath GF, Lye LF, Segawa H, Sacks DL, Turco SJ, Beverley SM. Persistence without pathology in phosphoglycandeficient Leishmania major. Science 2003; 301: 1241-1243.
105. Veras P, Brodskyn C, Balestieri F, Freitas L, Ramos A, Queiroz A, et al. A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem Inst Oswaldo Cruz 1999; 94: 491-496.